Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction

Henning Steen, Stephanie Lehrke, Uwe K H Wiegand, Constanze Merten, Lydia Schuster, Gert Richardt, Christian Kulke, Hans B. Gehl, Joao Lima, Hugo A. Katus, Evangelos Giannitsis

Research output: Contribution to journalArticle

Abstract

Background: Assessment of myocardial blood flow is important for identification and monitoring of microvascular effects of glycoprotein IIb/IIIa inhibitors. Magnetic resonance imaging is a novel noninvasive method providing complementary information on myocardial blood flow and cardiac function. Methods and Results: Patients (n = 53) admitted within 12 (mean, 5.8) hours after onset of symptoms were randomized to tirofiban or standard therapy before primary percutaneous coronary intervention (PCI) with stenting. Myocardial blood flow was graded by measurement of corrected Thrombolysis in Myocardial Infarction frame counts and by semiquantitative analysis of signal intensity curves from first-pass contrast-enhanced magnetic resonance perfusion. Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P =. 008) indicating improved myocardial blood flow. Magnetic resonance imaging revealed higher normalized peak signal intensities (2.19 vs 1.63, P =. 046) and a trend to steeper upslopes (0.79 vs 0.48, P =. 1). Cardiac left ventricular wall motion analysis resulted in a significantly lower number of myocardial segments with abnormal wall thickening (6.4 vs 8.5, P =. 025). Conclusions: Pretreatment with tirofiban appears safe and improves myocardial flow after primary PCI with stenting. Magnetic resonance imaging proved useful as a complementary method for noninvasive assessment of myocardial blood flow and cardiac function in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume149
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

tirofiban
Percutaneous Coronary Intervention
Perfusion
Magnetic Resonance Imaging
Myocardial Infarction
Platelet Glycoprotein GPIIb-IIIa Complex
Magnetic Resonance Spectroscopy
ST Elevation Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. / Steen, Henning; Lehrke, Stephanie; Wiegand, Uwe K H; Merten, Constanze; Schuster, Lydia; Richardt, Gert; Kulke, Christian; Gehl, Hans B.; Lima, Joao; Katus, Hugo A.; Giannitsis, Evangelos.

In: American Heart Journal, Vol. 149, No. 3, 03.2005.

Research output: Contribution to journalArticle

Steen, Henning ; Lehrke, Stephanie ; Wiegand, Uwe K H ; Merten, Constanze ; Schuster, Lydia ; Richardt, Gert ; Kulke, Christian ; Gehl, Hans B. ; Lima, Joao ; Katus, Hugo A. ; Giannitsis, Evangelos. / Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction. In: American Heart Journal. 2005 ; Vol. 149, No. 3.
@article{46334202d8fa41abb1ac85bced0862c0,
title = "Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction",
abstract = "Background: Assessment of myocardial blood flow is important for identification and monitoring of microvascular effects of glycoprotein IIb/IIIa inhibitors. Magnetic resonance imaging is a novel noninvasive method providing complementary information on myocardial blood flow and cardiac function. Methods and Results: Patients (n = 53) admitted within 12 (mean, 5.8) hours after onset of symptoms were randomized to tirofiban or standard therapy before primary percutaneous coronary intervention (PCI) with stenting. Myocardial blood flow was graded by measurement of corrected Thrombolysis in Myocardial Infarction frame counts and by semiquantitative analysis of signal intensity curves from first-pass contrast-enhanced magnetic resonance perfusion. Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P =. 008) indicating improved myocardial blood flow. Magnetic resonance imaging revealed higher normalized peak signal intensities (2.19 vs 1.63, P =. 046) and a trend to steeper upslopes (0.79 vs 0.48, P =. 1). Cardiac left ventricular wall motion analysis resulted in a significantly lower number of myocardial segments with abnormal wall thickening (6.4 vs 8.5, P =. 025). Conclusions: Pretreatment with tirofiban appears safe and improves myocardial flow after primary PCI with stenting. Magnetic resonance imaging proved useful as a complementary method for noninvasive assessment of myocardial blood flow and cardiac function in patients with ST-segment elevation myocardial infarction undergoing primary PCI.",
author = "Henning Steen and Stephanie Lehrke and Wiegand, {Uwe K H} and Constanze Merten and Lydia Schuster and Gert Richardt and Christian Kulke and Gehl, {Hans B.} and Joao Lima and Katus, {Hugo A.} and Evangelos Giannitsis",
year = "2005",
month = "3",
doi = "10.1016/j.ahj.2004.06.023",
language = "English (US)",
volume = "149",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction

AU - Steen, Henning

AU - Lehrke, Stephanie

AU - Wiegand, Uwe K H

AU - Merten, Constanze

AU - Schuster, Lydia

AU - Richardt, Gert

AU - Kulke, Christian

AU - Gehl, Hans B.

AU - Lima, Joao

AU - Katus, Hugo A.

AU - Giannitsis, Evangelos

PY - 2005/3

Y1 - 2005/3

N2 - Background: Assessment of myocardial blood flow is important for identification and monitoring of microvascular effects of glycoprotein IIb/IIIa inhibitors. Magnetic resonance imaging is a novel noninvasive method providing complementary information on myocardial blood flow and cardiac function. Methods and Results: Patients (n = 53) admitted within 12 (mean, 5.8) hours after onset of symptoms were randomized to tirofiban or standard therapy before primary percutaneous coronary intervention (PCI) with stenting. Myocardial blood flow was graded by measurement of corrected Thrombolysis in Myocardial Infarction frame counts and by semiquantitative analysis of signal intensity curves from first-pass contrast-enhanced magnetic resonance perfusion. Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P =. 008) indicating improved myocardial blood flow. Magnetic resonance imaging revealed higher normalized peak signal intensities (2.19 vs 1.63, P =. 046) and a trend to steeper upslopes (0.79 vs 0.48, P =. 1). Cardiac left ventricular wall motion analysis resulted in a significantly lower number of myocardial segments with abnormal wall thickening (6.4 vs 8.5, P =. 025). Conclusions: Pretreatment with tirofiban appears safe and improves myocardial flow after primary PCI with stenting. Magnetic resonance imaging proved useful as a complementary method for noninvasive assessment of myocardial blood flow and cardiac function in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

AB - Background: Assessment of myocardial blood flow is important for identification and monitoring of microvascular effects of glycoprotein IIb/IIIa inhibitors. Magnetic resonance imaging is a novel noninvasive method providing complementary information on myocardial blood flow and cardiac function. Methods and Results: Patients (n = 53) admitted within 12 (mean, 5.8) hours after onset of symptoms were randomized to tirofiban or standard therapy before primary percutaneous coronary intervention (PCI) with stenting. Myocardial blood flow was graded by measurement of corrected Thrombolysis in Myocardial Infarction frame counts and by semiquantitative analysis of signal intensity curves from first-pass contrast-enhanced magnetic resonance perfusion. Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P =. 008) indicating improved myocardial blood flow. Magnetic resonance imaging revealed higher normalized peak signal intensities (2.19 vs 1.63, P =. 046) and a trend to steeper upslopes (0.79 vs 0.48, P =. 1). Cardiac left ventricular wall motion analysis resulted in a significantly lower number of myocardial segments with abnormal wall thickening (6.4 vs 8.5, P =. 025). Conclusions: Pretreatment with tirofiban appears safe and improves myocardial flow after primary PCI with stenting. Magnetic resonance imaging proved useful as a complementary method for noninvasive assessment of myocardial blood flow and cardiac function in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

UR - http://www.scopus.com/inward/record.url?scp=17844379981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844379981&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.06.023

DO - 10.1016/j.ahj.2004.06.023

M3 - Article

C2 - 15864217

AN - SCOPUS:17844379981

VL - 149

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -